Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00189176 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis
A Phase 1 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00189176 is a Phase 1 study that has completed, run by University of Michigan. The registered enrollment target is 23 participants.
The verdict
NCT00189176, a Phase 1 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study will evaluate the safety of the administration of a copper chelating agent, tetrathiomolybdate, for patients with idiopathic pulmonary fibrosis that have failed previous treatment. The primary endpoint for this study is safety with secondary endpoints including change in pulmonary function, exercise capacity, and quality of life.
Interventions
- DRUG Tetrathiomolybdate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2003-03 |
| Est. Completion | 2006-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00189176
The ClinicalTrials.gov registry entry for NCT00189176 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tetrathiomolybdate is the first listed.
NCT00189176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00189176 about?
NCT00189176 is a clinical study titled "Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis". This study will evaluate the safety of the administration of a copper chelating agent, tetrathiomolybdate, for patients with idiopathic pulmonary fibrosis that have failed previous treatment. The primary endpoint for this study is safety with secondary endpoints including change in pulmonary functio...
What is the current status of trial NCT00189176?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2003-03. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00189176?
The interventions under investigation include: Tetrathiomolybdate (DRUG).
Who is sponsoring clinical trial NCT00189176?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.